Wednesday, October 08, 2025 IND.238 sub-study A is a phase II study of Durvalumab in patients who discontinued prior checkpoint therapy due to immune related toxicity has closed to accrual. Treatment and follow up for sub-study A patients will continue as per protocol. The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with durvalumab, can reduce any side effects.
